Early Health benefits and obstacles revealed by EU study

7 October 2007

A survey of senior health care policy makers and advisors across the European Union's member states, announced at GE Healthcare's media summit in Berlin, Germany, shows widespread support for an increase in early health initiatives such as prevention, screening and early diagnosis, but not at the expense of current health care budgets allocated for treatment.

The qualitative research carried out this August by Total Healthcare Solutions on behalf of GE Healthcare provides a snapshot view of current opinions of 15 health care policy makers and advisors across the European Union, including new accession countries (the Czech Republic, Poland, Hungary, Slovenia and Latvia). It also identifies investment opportunities and challenges for Early Health.

The findings indicate a general consensus that Early Health initiatives should increase as part of a long-term plan to reduce the cost burden of treating disease in an aging population, and in order to reduce suffering from chronic disease. However, a range of barriers and challenges that limit the willingness of governments to invest in Early Health programs were also identified by the study's authors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight